South Korea
· Delayed Price · Currency is KRW GC Genome Company Description
GC Genome Corporation operates as a clinical genome analysis company in South Korea.
It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing.
The company also provides ai-CANCERCH, an AI algorithm-based multi-cancer early screening test; Jins Sketch, a genetic test for personalized nutrition; Genome Health and Risk Screen that identifies various disease-susceptibility genes; Green Biome for human symbiotic microorganism genetic analysis service; Genome Screen, an optimal genetic test for preemptive action; Telorisk, an indicator of biological age; and drug compatibility DNA test.
In addition, it offers G-NIPT, a noninvasive fetal chromosomal abnormality screening test; Prenatal CMA, a diagnostic test for fetal chromosomal abnormalities with higher diagnostic value; i-screen for newborn genetic screening; and dd-cfDNA, a single nucleotide polymorphism test of cell-free nucleic acid derived from organ transplant donors.
The company was founded in 2013 and is based in Yongin-si, South Korea.
| Country | South Korea |
| Founded | 2013 |
| Industry | Medical - Equipment & Services |
| Sector | Healthcare |
| CEO | Chang-Seok Ki |
Contact Details
Address: 107, Ihyeon-ro 30beon-gil Yongin-si, 16924 South Korea | |
| Phone | 82 3 1280 9900 |
| Website | gcgenome.com |
Stock Details
| Ticker Symbol | 340450 |
| Exchange | KOSDAQ |
| Reporting Currency | KRW |
| ISIN Number | KR7340450006 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Chang-Seok Ki | Chief Executive Officer |